A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01802138
Recruitment Status : Active, not recruiting
First Posted : March 1, 2013
Last Update Posted : April 28, 2017
Information provided by (Responsible Party):
Seoul National University Hospital

Brief Summary:
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed neuroblastoma patients.

Condition or disease Intervention/treatment
Neuroblastoma Biological: Activated T lymphocyte

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
Study Start Date : February 2013
Primary Completion Date : June 2016
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Activated T-lymphocyte

This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.

If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated.

Biological: Activated T lymphocyte
intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
Other Name: Immuncell-LC

Primary Outcome Measures :
  1. T cell count after in vitro expansion [ Time Frame: up to 13 weeks ]

    T cell count after in vitro expansion

    Evaluation of safety

Secondary Outcome Measures :
  1. Number of participants who showed response with Response Evaluation Criteria in Solid Tumors criteria [ Time Frame: up to 1 year ]

    To determine the response rate

    To evaluate 1 yr progression free survival and overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent
  • Age 21 years or younger
  • Histologically confirmed neuroblastoma
  • Progressive disease after standard treatment or relapsed patient
  • ECOG scale (ECOG-PS) ≤2
  • Expected survival at least 3 months

Exclusion Criteria:

  • Patients with autoimmune disease
  • Patients with immunodeficiency
  • Other malignancy 5 year prior to this study
  • Severe organ dysfunction
  • Severe allergic disease
  • Severe psychiatric disorder
  • Pregnancy or lactating woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01802138

Korea, Republic of
Seoul National University Hospital
Seoul, Chongno-gu, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital

Responsible Party: Seoul National University Hospital Identifier: NCT01802138     History of Changes
Other Study ID Numbers: ILC_IIT_03
First Posted: March 1, 2013    Key Record Dates
Last Update Posted: April 28, 2017
Last Verified: April 2017

Keywords provided by Seoul National University Hospital:
refractory/relapsed neuroblastoma patients

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue